Sio Gene Therapies
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sio Gene Therapies generated cash of -$60,346,000, which is less than the previous year. Cash used in financing activities reached the amount of $1,441,000 last year. Net change in cash is therefore -$55,257,000.
Cash Flow
| 2016 | -53.34M | -5.34M | 334.94M |
|---|---|---|---|
| 2017 | -112.10M | -105K | 48.53M |
| 2018 | -190.34M | -4.28M | 136.39M |
| 2019 | -134.20M | -202K | 87.07M |
| 2020 | -67.47M | -255K | 41.48M |
| 2021 | -46.58M | 12.38M | 73.62M |
| 2022 | -60.34M | 3.64M | 1.44M |
SIOX Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 120.17M | 80.75M | 106.99M | 154.33M | 212.57M | 276.25M | 0 |
Operating activities | |||||||
Net income | -71.88M | -32.42M | -72.62M | -129.06M | -221.57M | -180.95M | -133.14M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 666K | 2.46M | 3.09M | 2.45M | 3.08M | 249K | 14K |
Stock-based compensation expense | 7.42M | 4.49M | 7.89M | 16.42M | 31.87M | 36.37M | 72.38M |
| Deferred income tax benefit | 7.42M | 4.49M | 7.89M | 16.42M | 31.87M | 36.37M | 72.38M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.64M | -3.07M | 2.71M | -2.25M | -4.60M | 7.92M | 219K |
Cash generated by operating activities | -60.34M | -46.58M | -67.47M | -134.20M | -190.34M | -112.10M | -53.34M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -695K | -398K | -255K | -202K | -4.28M | -105K | -5.34M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 3.64M | 12.38M | -255K | -202K | -4.28M | -105K | -5.34M |
Financing activities | |||||||
Common Stock Issued | 1.44M | 89.23M | 70.81M | 94.54M | 134.51M | 0 | 336.89M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -15.73M | -29.56M | 0 | 0 | 0 | -627K |
Cash used in financing activities | 1.44M | 73.62M | 41.48M | 87.07M | 136.39M | 48.53M | 334.94M |
Net Change In Cash | -55.25M | 39.41M | -26.24M | -47.33M | -58.23M | -63.67M | 276.25M |
Cash at end of period | 64.91M | 120.17M | 80.75M | 106.99M | 154.33M | 212.57M | 276.25M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |